Daclatasvir Side Effects
The most common side effects of daclatasvir are fatigue, headache, and nausea, which are generally mild and well-tolerated. 1
Common Adverse Effects
Based on multiple international hepatology guidelines, daclatasvir demonstrates a favorable safety profile with the following most frequently reported adverse reactions:
- Fatigue - Most commonly reported systemic symptom
- Headache - Frequent neurological complaint
- Nausea - Primary gastrointestinal effect
- Diarrhea - Additional GI manifestation 2
When daclatasvir is combined with asunaprevir specifically, the adverse event profile expands slightly to include:
- Elevation of ALT (alanine aminotransferase) 2
Real-world data from treatment studies confirm these findings, with additional minor effects including lethargy, insomnia, and fever, all occurring at low frequencies 3.
Serious but Rare Adverse Events
While daclatasvir is generally well-tolerated, several serious adverse reactions have been documented in case reports and should be monitored:
Hepatobiliary Effects
- Severe hyperbilirubinemia without transaminitis - Can occur even in patients with cirrhosis, requiring drug discontinuation 4
- Drug-induced liver injury with immunoallergic mechanisms - Rare but can present with fever, skin rash, and coagulation disorders 5
- Cholecystitis - Reported in combination with hepatitis and disseminated intravascular coagulation 5
Pulmonary Effects
- Drug-induced lung injury - First documented case with daclatasvir/asunaprevir combination, representing an important though rare complication 6
Important Clinical Context
The adverse event profile is significantly more favorable than interferon-based regimens, which is why daclatasvir-containing regimens have become preferred treatments 3, 7. In clinical trials with daclatasvir plus sofosbuvir, the most common adverse events remained fatigue, headache, and nausea, with no serious safety concerns in the majority of patients 7.
Monitoring Considerations
When prescribing daclatasvir:
- Monitor liver transaminases, particularly when combined with asunaprevir (3-4% incidence of ALT/AST elevations) 2
- Watch for hyperbilirubinemia, especially in patients with advanced cirrhosis 4
- Be alert for immunoallergic reactions presenting as fever, rash, or multi-organ involvement 5
- Consider pulmonary symptoms as potential drug-induced lung injury, though extremely rare 6
Critical caveat: The FDA drug label provided 8 appears to describe doxycycline (a tetracycline antibiotic) rather than daclatasvir, and should be disregarded as it is not relevant to this HCV medication.
The overall safety profile supports daclatasvir as a well-tolerated direct-acting antiviral with predominantly mild, manageable side effects in the vast majority of patients.